Registration for a live webinar on 'Innate immunity, inflammation and cancer' is now open.
See webinar details
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Luminal Gastroenterology
-
31 min
1. Novel treatments for GI malignancies- Prof. Bert H. O'Neil
-
40 min
2. The spectrum of GERD implications for assessment and management- Prof. Eamonn M. M. Quigley
-
54 min
3. Oro-pharyngeal and esophageal motility and dysmotility- Dr. John E. Pandolfino
-
55 min
4. Eosinophilic esophagitis and other non-reflux esophageal disorders- Prof. David Katzka
-
39 min
-
17 min
-
48 min
-
48 min
8. Gastric cancer, gastritis and the role of H. pylori- Prof. Anthony Axon
-
48 min
9. Celiac disease- Prof. Ciaran Kelly
-
43 min
10. IBD for the non-gastroenterologist- Prof. Sunanda Kane
-
34 min
11. The enteric microbiota in health and disease- Dr. Francisco Guarner
-
45 min
12. Colorectal cancer and hereditary colon cancer syndromes- Prof. Carol A. Burke
-
39 min
13. The spectrum of GI ischemia 1- Prof. Lawrence J. Brandt
-
31 min
14. The spectrum of Gl ischemia 2- Prof. Lawrence J. Brandt
-
41 min
15. Constipation and defecation disorders- Prof. Satish S. C. Rao
-
40 min
16. Diverticular disease of the colon- Dr. Dale Vimalachandran
-
73 min
17. Irritable bowel syndrome (IBS)- Prof. Eamonn M. M. Quigley
-
27 min
18. Evidence-based management of non-variceal upper GI bleeding- Prof. Joseph J. Sung
- Hepatology
-
32 min
19. Hepatitis B virus (HBV)- Prof. Marco Olivera-Martinez
-
26 min
20. Hepatitis C - cure of infection- Prof. Mark Mailliard
-
46 min
21. Drug-induced liver injury: importance, epidemiology, and mechanisms of DILI- Prof. James H. Lewis
-
26 min
22. Drug-induced liver injury: risk factors and drug development in DILI- Prof. James H. Lewis
-
39 min
23. Drug-induced liver injury: HDS, diagnosing, treating and preventing DILI- Prof. James H. Lewis
-
22 min
24. Portal hypertension- Prof. John Reinus
-
55 min
25. Portal hypertension: at the bedside- Dr. Clara Y. Tow
-
29 min
26. The management of chronic liver disease, including transplantation 1- Prof. Timothy M. McCashland
-
21 min
27. The management of chronic liver disease, including transplantation 2- Prof. Timothy M. McCashland
-
34 min
28. Hereditary hemochromatosis: what have we learnt from population studies- Prof. John K. Olynyk
-
38 min
29. Immune-mediated liver disease- Dr. Jenny Heathcote
-
51 min
30. Alcoholic liver disease- Prof. Michael Lucey
- The Pancreas and Biliary Tree
-
51 min
31. Acute pancreatitis- Prof. Davor Štimac
-
49 min
32. Chronic pancreatitis- Prof. Christopher Forsmark
-
47 min
33. Pancreatic cancer- Prof. Randall Brand
-
20 min
- Archived Lectures *These may not cover the latest advances in the field
-
52 min
35. The management of other aspects of chronic liver disease, including transplantation- Prof. Timothy M. McCashland
-
38 min
36. Chronic viral hepatitis B and C- Prof. Mark Mailliard
-
41 min
37. Pancreatic cancer- Prof. Randall Brand
-
72 min
38. Acute viral hepatitis- Prof. Geoffrey Dusheiko
-
33 min
39. Diverticular disease- Dr. Charles Knowles
-
57 min
40. The spectrum of gastrointestinal ischemia: 2010- Prof. Lawrence J. Brandt
Printable Handouts
Navigable Slide Index
- Introduction
- Irritable Bowel Syndrome (IBS)
- What is IBS?
- "Classical" IBS is a coherent entity
- IBS in the "real" world!
- IBS features
- IBS: Rome III definition (1)
- IBS: Rome III definition (2)
- A more clinician-friendly definition?
- Criteria-based definition of IBS
- The irritable colon syndrome study (1)
- The irritable colon syndrome study (2)
- We have ignored the rest of the world!
- Global prevalence of IBS 2005
- Regional variations
- IBS pathophysiology
- The gut brain axis in IBS (1)
- The gut brain axis in IBS (2)
- A new paradigm
- Evidence for a role for the gut flora in IBS
- Post infectious IBS
- Walkerton, Ontario
- Long term outcome, does PI- IBS go away?
- CSGNA outbreak - Norovirus
- Lessons from PI- IBS
- Direct evidence of an altered gut flora, SIBO
- Another explanation for antibiotic effect in IBS?
- Altered colonic flora
- GI microbiota in IBS
- The fecal flora in IBS
- Colonic biofilm
- Physiological effects of an altered flora
- Altered flora causing alterations in gas volume
- Mediator of pro-inflammatory state
- Pro-inflammatory state
- Systemic and mucosal immune system
- Systemic compartment (1)
- Systemic immune compartment in IBS
- Alternative approach to IBS pathophysiology (1)
- IBS and somatic co-morbidity
- Alternative approach to IBS pathophysiology (2)
- Significance of changes in inflammatory markers
- ACTH response to CRH
- The mucosal immune system
- Mucosal compartment (1)
- Beta-defensin 2 in IBS
- Mucosal compartment (2)
- Can we link bacteria, inflammation and IBS?
- Is this a form of IBD?
- Calprotectin in IBS
- IBS symptoms in IBD?
- Crohn's Disease
- Ulcerative Colitis
- Therapeutic impact of altering flora
- Antibiotics
- Rifaximin
- Probiotics
- Anti-inflammatories
- Mesalazine in IBS
- Food, diet and IBS: role in pathophysiology
- Food intake and GI symptoms
- Food scores in IBS
- Why does food provoke symptoms in IBS?
- Physiological effects of food
- Diet and IBS
- Food allergy in IBS
- IgG responses in IBS (1)
- IgG responses in IBS (2)
- Gluten-reactive IBS (1)
- Gluten-reactive IBS (2)
- Food intolerance in IBS
- Diagnosis
- Yield of tests in IBS
- Prevalence of organic disease in IBS
- Management
- Food, diet and IBS: role in management
- Fiber/bulking agents for IBS
- Probiotics
- Prebiotics (1)
- Probiotics in IBS, pre 2000
- Probiotics in IBS, from 2000
- Study design
- Pain, VAS scale
- Composite score
- Systemic compartment (2)
- Bifidobacterium in IBS
- Abdominal pain or discomfort
- Bloating
- Global assessment of symptom relief
- Bif. animalis in C-IBS
- Bifidobacterium lactis DN 173 010 (1)
- Bifidobacterium lactis DN 173 010 (2)
- What about the long-term?
- Prebiotics (2)
- Prebiotics and synbiotics in IBS
- IBS: pharmacological and other approaches
- Antispasmodics
- Cochrane study
- Anti-depressants for IBS
- Anti-depressants in IBS
- New approaches
- Targets
- Challenges in drug development
- Significance
- New targets (1)
- Serotonin
- Tegaserod
- Alosetron
- New targets (2)
- Lubiprostone in C-IBS
- Psychotherapy and hypnotherapy
- What do we need to know?
- Conclusions
Topics Covered
- A common symptom-based disorder which affects 5-15% of the adult population world-wide
- For some, symptoms can be severe, frequent and significantly impact on quality of life
- Commonly regarded as reflecting a dysfunction of the gut-brain axis, low grade inflammation and dysbiosis of the microbiota have been implicated of late
- Management continues to be challenging with approaches which aim to alleviate individual symptoms (pain, constipation, diarrhoea) continuing to dominate in the absence of truly disease-modifying therapies.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Quigley, E.M.M. (2011, January 5). Irritable bowel syndrome (IBS) [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 19, 2024, from https://hstalks.com/bs/1913/.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Eamonn M. M. Quigley, Consultant: Alimentary Health, Allergen, Commonwealth Laboratories, Rhythm, Salix, Synergy, Vibrant Speaker’s Bureau: Procter and Gamble Grant/Research Support (Principal Investigator): Rhythm, Therevance, Vibrant Stock Shareholder (Self-managed): Alimentary Health
Irritable bowel syndrome (IBS)
Published on January 5, 2011
73 min
